The role of cediranib in ovarian cancer: current status and further investigation

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Mcguire W, Hoskins WJ, Brady M, et al. Cyclophosphamid and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.
   PubMed Web of Science ®Google Scholar
• Winter WE 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(24):3621–3627.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.
   PubMed Web of Science ®Google Scholar
• Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol. 2007;64(2):129–138.
   PubMed Web of Science ®Google Scholar
• Rose P, Fusco N, Fluellen L, et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol. 1998;16(4):1494.
   PubMed Web of Science ®Google Scholar
• Naumann R, Coleman R. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011;71(11):1397–1412.
   PubMed Web of Science ®Google Scholar
• Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 2008;5(4):194–204.
   PubMedGoogle Scholar
• Schmitt J, Matei D. Targeting angiogenesis in ovarian cancer. Cancer Treat Rev. 2012;38(4):272–283.
   PubMed Web of Science ®Google Scholar
• Klempner SJ, Myers AP, Mills GB, et al. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother. 2013;14(16):2171–2182.
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–2496.
   PubMed Web of Science ®Google Scholar
• Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139(1):10–16.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–1308.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–2045.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(8):799–808.
   PubMed Web of Science ®Google Scholar
• Tew WP, Colombo N, Ray-Coquard I, et al. Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer. 2014;120(3):335–343.
   PubMed Web of Science ®Google Scholar
• du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374–3382.
   PubMed Web of Science ®Google Scholar
• Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013;11(2):172–191.
   PubMedGoogle Scholar
• Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65(10):4389–4400.
   PubMed Web of Science ®Google Scholar
• Brave SR, Ratcliffe K, Wilson Z, et al. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol Cancer Ther. 2011;10(5):861–873.
   PubMed Web of Science ®Google Scholar
• Heckman CA, Holopainen T, Wirzenius M, et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008;68(12):4754–4762.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Wong RP, D’Haens G, et al. Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. Br J Cancer. 2013;108(3):493–502.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol. 2012;30(29):3588–3595.
   PubMed Web of Science ®Google Scholar
• Hoff PM, Hochhaus A, Pestalozzi BC, et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol. 2012;30(29):3596–3603.
   PubMed Web of Science ®Google Scholar
• Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol. 2010;28(1):49–55.
   PubMed Web of Science ®Google Scholar
• Laurie SA, Solomon BJ, Seymour L, et al. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer. 2014;50(4):706–712.
   PubMed Web of Science ®Google Scholar
• Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–1214.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Embleton AC, Raja F, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387(10023):1066–1074.
   PubMed Web of Science ®Google Scholar
• Symonds RP, Gourley C, Davidson S, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2015;16(15):1515–1524.
   PubMed Web of Science ®Google Scholar
• Public summary of opinion on orphan designation: cediranib for the treatment of ovarian cancer. London: European Medicines Agency; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2014/09/WC500171953.pdf
   Google Scholar
• Mitchell CL, O’Connor JP, Roberts C, et al. A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother Pharmacol. 2011;68(3):631–641.
   PubMed Web of Science ®Google Scholar
• Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25(21):3045–3054.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Tamura T, Yamamoto N, et al. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009;64(6):1165–1172.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601–5606.
   PubMed Web of Science ®Google Scholar
• Hirte H, Lheureux S, Fleming GF, et al. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia. Gynecol Oncol. 2015;138(1):55–61.
   PubMed Web of Science ®Google Scholar
• Decio A, Taraboletti G, Patton V, et al. Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol. 2014;184(4):1050–1061.
   PubMed Web of Science ®Google Scholar
• Decio A, Cesca M, Bizzaro F, et al. Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. Clin Exp Metastasis. 2015;32(7):647–658.
   PubMed Web of Science ®Google Scholar
• Liu JF, Tolaney SM, Birrer M, et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013;49(14):2972–2978.
   PubMed Web of Science ®Google Scholar
• Arnaudeau C, Lundin C, Helleday T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol. 2001;307:1235–1245.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Oza AM. Olaparib for the treatment of ovarian cancer. Expert Opinion Orphan Drugs. 2014;2(5):497–508.
   Web of Science ®Google Scholar
• Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785–3790.
   PubMed Web of Science ®Google Scholar
• Rigakos G, Razis E. BRCAness: finding the achilles heel in ovarian cancer. Oncologist. 2012;17(7):956–962.
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852–861.
   PubMed Web of Science ®Google Scholar
• Audeh MWA, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376:245–251.
   PubMed Web of Science ®Google Scholar
• Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–250.
   PubMed Web of Science ®Google Scholar
• Dean E, Middleton MR, Pwint T, et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer. 2012;106(3):468–474.
   PubMed Web of Science ®Google Scholar
• Lee JM, Trepel JB, Choyke P, et al. CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer. Front Oncol. 2015. 5 (JUN) (123)
   Web of Science ®Google Scholar
• Liu J. Olaparib or cediranib maleate and olaparib compared with standard platinum-based chemotherapy in treating patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer (NCT02446600). In: ClinicalTrialsgov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000–2016.
   Google Scholar
• Oza A. e-Volve: a study of cediranib and olaparib at the time ovarian cancer worsens on olaparib (NCT02340611). In: ClinicalTrialsgov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000–2016.
   Google Scholar
• Lee J-M. Cediranib maleate and olaparib or standard chemotherapy in treating patients with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS) (NCT02502266). In: ClinicalTrialsgov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000–2016.
   Google Scholar
• Ledermann J, Perren TJ, Raja FA, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Eur J Cancer. 2013;49(Supplement 3):S5.
   Google Scholar
• Ivy SP, Liu JF, Lee JM, et al. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Expert Opin Investig Drugs. 2016;25(5):597–611.
   PubMed Web of Science ®Google Scholar
• Norrie J. ICON-6: the danger of changing study design midstream. Lancet. 2016;387(10023):1031–1032.
   PubMed Web of Science ®Google Scholar
• Hong DS, Garrido-Laguna I, Ekmekcioglu S, et al. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014;120(14):2164–2173.
   PubMed Web of Science ®Google Scholar
• Lorusso P, Shields AF, Gadgeel S, et al. Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Invest New Drugs. 2011;29(6):1395–1405.
   PubMed Web of Science ®Google Scholar
• Mitchell CL, O’Connor JPB, Roberts C, et al. A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother Pharmacol. 2011;68(3):631–641.
   PubMed Web of Science ®Google Scholar
• Mulder SF, Boers-Sonderen MJ, van der Heijden HF, et al. A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion. Target Oncol. 2014;9(4):331–338.
   PubMed Web of Science ®Google Scholar
• Sahebjam S, Bedard PL, Castonguay V, et al. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br J Cancer. 2013;109(4):943–949.
   PubMed Web of Science ®Google Scholar
• Trarbach T, Schultheis B, Gauler TC, et al. Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours. Invest New Drugs. 2012;30(5):1962–1971.
   PubMed Web of Science ®Google Scholar
• van Cruijsen H, Voest EE, Punt CJA, et al. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur J Cancer. 2010;46(5):901–911.
   PubMed Web of Science ®Google Scholar
• van Herpen CML, Lassen U, Desar IME, et al. Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment. Anti-Cancer Drugs. 2013;24(2):204–211.
   PubMed Web of Science ®Google Scholar
• Bender D, Sill MW, Lankes HA, et al. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015;138(3):507–512.
   PubMed Web of Science ®Google Scholar
• Chen E, Jonker D, Gauthier I, et al. Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. Clin Cancer Res. 2009;15(4):1481–1486.
   PubMed Web of Science ®Google Scholar
• Satoh T, Yamaguchi K, Boku N, et al. Phase i results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. Invest New Drugs. 2012;30(4):1511–1518.
   PubMed Web of Science ®Google Scholar
• Kato T, Muro K, Yamaguchi K, et al. Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. Ann Oncol. 2012;23(4):933–941.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol. 2012;30(29):3588–3595.
   PubMed Web of Science ®Google Scholar
• Hoff PM, Hochhaus A, Pestalozzi BC, et al. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol. 2012;30(29):3596–3603.
   PubMed Web of Science ®Google Scholar
• Satoh T, Yamada Y, Muro K, et al. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 2012;69(2):439–446.
   PubMed Web of Science ®Google Scholar
• Alberts SR, Fitch TR, Kim GP, et al. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol. 2012;35(4):329–333.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Ancukiewicz M, Supko JG, et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013;19(6):1557–1566.
   PubMed Web of Science ®Google Scholar
• Valle JW, Wasan H, Lopes A, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 2015;16(8):967–978. [Erratum appears in Lancet Oncol. 2015 Sep;16(9):e427;PMID: 26370352]
   PubMed Web of Science ®Google Scholar
• Campbell NP, Kunnavakkam R, Leighl N, et al. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012;78(1):76–80.
   PubMed Web of Science ®Google Scholar
• Garland LL, Chansky K, Wozniak AJ, et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol. 2011;6(11):1938–1945.
   PubMed Web of Science ®Google Scholar
• Goss G, Shepherd FA, Laurie S, et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer. 2009;45(5):782–788.
   PubMed Web of Science ®Google Scholar
• Laurie SA, Gauthier I, Arnold A, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2008;26(11):1871–1878.
   PubMed Web of Science ®Google Scholar
• Dy GK, Mandrekar SJ, Nelson GD, et al. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. J Thorac Oncol. 2013;8(1):79–88.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Belani CP, Mac KPC, et al. Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010;5(8):1279–1284.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Stadler WM, Roth B, et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007;25(5):445–451.
   PubMed Web of Science ®Google Scholar
• Dahut WL, Madan RA, Karakunnel JJ, et al. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int. 2013;111(8):1269–1280.
   PubMed Web of Science ®Google Scholar
• Spreafico A, Chi KN, Sridhar SS, et al. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs. 2014;32(5):1005–1016.
   PubMed Web of Science ®Google Scholar
• Mulders P, Hawkins R, Nathan P, et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer. 2012;48(4):527–537.
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Mackenzie MJ, Hotte SJ, et al. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Invest New Drugs. 2013;31(4):1008–1015.
   PubMed Web of Science ®Google Scholar
• Pinho MC, Polaskova P, Kalpathy-Cramer J, et al. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist. 2014;19(1):75–81.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Duda DG, Di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28(17):2817–2823.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26):3212–3218.
   PubMed Web of Science ®Google Scholar
• Judson I, Scurr M, Gardner K, et al. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clin Cancer Res. 2014;20(13):3603–3612.
   PubMed Web of Science ®Google Scholar
• Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol. 2013;31(18):2296–2302.
   PubMed Web of Science ®Google Scholar
• Hyams DM, Chan A, de Oliveira C, et al. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Invest New Drugs. 2013;31(5):1345–1354.
   PubMed Web of Science ®Google Scholar